Hi Bob,
I believe these are two separate studies.
UCL is a research arm of the U of London, UCL.
This study, that Olsen is referencing, is about the kind of "piggy-backing" a medication with a substance that can pass the BBB- in this case a peptide.
The previous study was about attempting to maintain the integrity of the BBB
against the onslaught of MS and other neurodegenerative problems which break it down.
At least, that is how I interpreted the two studies.